Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #6873
Reference
MSAN(2020)25
Name
H2-antagonists (cimetidine, famotidine and nizatidine) – update to MSAN (2020)11
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
1. Following supply issues affecting Ranitidine (MSAN (2019)22, and subsequent updates), suppliers of cimetidine, famotidine and nizatidine have reported an increase in demand, which has contributed to short term shortages.
- Famotidine 20mg tablets are out of stock until 14 April 2020 (Tillomed) and May 2020 (Teva).
- Famotidine 40mg tablets are out of stock until April 2020 (Teva).
- Cimetidine 200mg tablets are out of stock until 30 March 2020 (Ennogen) and January 2021 (Medley Pharma).
- Cimetidine 400mg tablets are out of stock until 30 March 2020 (Ennogen) and 30 August 2020 (Medreich).
- Cimetidine 800mg tablets are out of stock until 30 March 2020 (Ennogen).
- Nizatidine 150mg and 300mg tablets are out of stock with no confirmed resupply date (Medreich and Mylan).
2. It is recommended that, where possible, patients are not switched to an alternative H2-receptor antagonist in the first instance as this may exacerbate a shortage of these products. There are currently sufficient supplies of oral omeprazole to manage an increase in demand.
Contact Name
Contact Email
Contact Address
Created
2020-04-23 00:00:00
Click to go back to homepage